[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Ramia JM, Sancho E, Lozano O, Santos JM, Garrido F: [Primary small bowel lymphoma]. Cir Esp; 2007 Jan;81(1):46-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary small bowel lymphoma].
  • We present four patients with non-Hodgkin's lymphoma of the small bowel.
  • Three patients had large B-cell lymphomas and the remaining patient had a T-cell lymphoma associated with celiac disease.
  • Different combinations of chemotherapy were administered.
  • Only the patient with T-cell lymphoma died due to disease progression.
  • Clinical aspects and the therapeutic strategy used in these tumors are discussed.
  • [MeSH-major] Ileal Neoplasms. Jejunal Neoplasms. Lymphoma, Large B-Cell, Diffuse. Lymphoma, T-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263959.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Nomura K, Tomikashi K, Matsumoto Y, Yoshida N, Okuda T, Sakakura C, Mitsufuji S, Horiike S, Yamagishi H, Okanoue T, Taniwaki M: Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy. World J Gastroenterol; 2005 Jul 28;11(28):4443-4
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy.
  • Because distention of fluid- and gas-filled loops of small intestine was proved by X-ray, the patient was diagnosed as having small bowel obstruction.
  • A laparotomy revealed a segmental stenosis in the jejunum, which showed diffuse thickening of the intestinal wall.
  • We diagnosed diffuse large B-cell lymphoma based on the pathological findings of diffuse transmural infiltration of large lymphoid cells and flow-cytometric analyses.
  • Rituximab was administered as adjuvant therapy at weekly doses of 375 mg/m2.
  • Rituximab may be effective as adjuvant therapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / surgery. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Humans. Male. Remission Induction. Rituximab

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038051.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC4434679
  •  go-up   go-down


3. Al-Sayes FM: Gastrointestinal Non-Hodgkin's lymphoma: a clinico-pathological study. Saudi J Gastroenterol; 2006 Sep-Dec;12(3):118-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal Non-Hodgkin's lymphoma: a clinico-pathological study.
  • OBJECTIVES: The aim of this study is to determine the clinico-pathological features of primary gastrointestinal non-Hodgkin's lymphoma (GI NHL) at King Abdulaziz University Hospital, Jeddah, and to compare our results to those reported in the literature.
  • MATERIALS AND METHODS: Twenty-three adult patients with primary GI NHL diagnosed over a 5-year period (2000 through 2005) were retrospectively studied clinically and histopathologically.
  • RESULTS: Of the 23 patients with primary GI NHL, 14 (60.9%) were Saudis, with a male-to-female ratio of 1.3:1.
  • Abdominal pain was the most common presenting symptom (78.3%), and the most common primary site was the stomach (73.9%), followed by the small bowel (13%).
  • The most frequent histologic subtype was the diffuse large B cell lymphoma, accounting for 60.9% of all cases, followed by the marginal-zone cell lymphoma (MALT type), which was Helicobacter pylori associated (39.1%).
  • A large proportion of patients with primary GI NHL had early disease (Stage IE - 20%, Stage IIE - 58.6%).
  • With regards to treatment, 15 patients (65.2%) had chemotherapy, while only 2 patients (8.7%) were treated by Helicobacter pylori eradication.
  • CONCLUSION: The data demonstrated that primary GI NHL is more common among males, mainly in their sixth decade.
  • Diffuse large B cell lymphoma is the most frequent histologic subtype, followed by extranodal marginal-zone B cell lymphoma (MALT type), which was Helicobacter-associated.
  • A majority of cases have early disease (stage IE and IIE), mostly treated by combination chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858597.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


Advertisement
4. Toubai T, Tanaka J, Ota S, Mori A, Ibata M, Shono Y, Mashiko S, Sugita J, Miura Y, Kato N, Umehara S, Kahata K, Toyoshima N, Asaka M, Imamura M: Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy. Intern Med; 2005 May;44(5):476-9
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy.
  • A 56-year-old man was admitted for treatment of non-Hodgkin's lymphoma (NHL).
  • He had undergone a partial small bowel and colon resection and had ileostomy due to bowel perforation induced by chemotherapy.
  • After the operation, his disease status was in partial remission (PR), and reduced-intensity allogeneic stem cell transplantation (RIST) was therefore performed for further improvement of disease status.
  • Graft-versus-host disease (GVHD) prophylaxis was performed using cyclosporin and short-term methotrexate.
  • [MeSH-major] Ileostomy. Intestinal Perforation / surgery. Lymphoma, Large B-Cell, Diffuse / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Biopsy. Colon / radiography. Colon / radionuclide imaging. Colon / surgery. Follow-Up Studies. Humans. Male. Mediastinum / pathology. Mediastinum / radiography. Mediastinum / radionuclide imaging. Middle Aged. Positron-Emission Tomography. Rupture, Spontaneous. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942098.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Salemis NS, Tsiambas E, Liatsos C, Karameris A, Tsohataridis E: Small bowel intussusception due to a primary non-Hodgkin's lymphoma. An unusual presentation and clinical course. J Gastrointest Cancer; 2010 Dec;41(4):233-7
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel intussusception due to a primary non-Hodgkin's lymphoma. An unusual presentation and clinical course.
  • Symptoms and signs are often vague and non-specific making a preoperative diagnosis difficult.
  • The purpose of this study is to present a rare case of a jejuno-jejunal intussusception due to primary intestinal non-Hodgkin's lymphoma in a patient with an unusual clinical course.
  • Computed tomography scan and ultrasonography findings were suggestive of small bowel intussusception.
  • RESULTS: Laparotomy revealed a jejuno-jejunal intussusception caused by a primary B cell non-Hodgkin's lymphoma 20 cm distal to the ligament of Treitz.
  • The patient refused postoperative adjuvant chemotherapy.
  • Seven months later, he presented with upper gastrointestinal bleeding, and the diagnostic evaluation revealed gastric infiltration of large B cell non-Hodgkin's lymphoma.
  • Despite chemotherapy, he died of disseminated progressive disease 7 months later.
  • CONCLUSIONS: Adult jejuno-jejunal intussusception due to primary non-Hodgkin's lymphoma is a rare clinical entity.
  • Appropriate investigations can lead to a prompt preoperative diagnosis.
  • Resection without prior reduction is the treatment of choice.
  • Our patient's refusal of postoperative adjuvant chemotherapy likely resulted in relapse of the disease in another part of the gastrointestinal tract.
  • [MeSH-major] Intussusception / etiology. Jejunal Neoplasms / complications. Jejunal Neoplasms / pathology. Lymphoma, B-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1971 May;121(5):531-5 [5557762.001]
  • [Cites] Am J Surg. 1997 Feb;173(2):88-94 [9074370.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):339-44 [15101721.001]
  • [Cites] Int J Hematol. 2008 May;87(4):375-81 [18409078.001]
  • [Cites] Haematologica. 2000 Apr;85(4):372-80 [10756362.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1546-51 [16990978.001]
  • [Cites] J Am Coll Surg. 1999 Apr;188(4):390-5 [10195723.001]
  • [Cites] Radiol Clin North Am. 2008 Mar;46(2):287-312, ix [18619382.001]
  • [Cites] J Gastrointest Cancer. 2009;40(3-4):79-82 [19937400.001]
  • [Cites] Abdom Imaging. 2000 Jan-Feb;25(1):45-7 [10652920.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):230-6 [7469558.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Ann Surg. 1997 Aug;226(2):134-8 [9296505.001]
  • [Cites] Clin Radiol. 1998 Jan;53(1):53-7 [9464437.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):305-8 [9234576.001]
  • [Cites] Int J Colorectal Dis. 2006 Dec;21(8):834-9 [15951987.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] J Surg Oncol. 2008 Nov 1;98(6):444-7 [18668640.001]
  • [Cites] J Int Med Res. 2007 May-Jun;35(3):406-15 [17593870.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):343-7 [12612513.001]
  • (PMID = 20411355.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Olnes MJ, Nicol T, Duncan M, Bohlman M, Erlich R: Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy. Leuk Lymphoma; 2002 Apr;43(4):817-21
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy.
  • Patients with this malignancy have been treated with chemotherapy regimens used against non-Hodgkin's lymphomas.
  • Staging of the tumor with CT scan, PET scan, and bone marrow biopsy demonstrated inguinal and abdominal lymphadenopathies, a large mass encasing the small bowel, and extensive liver infiltration.
  • Morphologic and cytochemical analysis of biopsies from the abdominal mass and inguinal node were consistent with a diagnosis of IDCS, and immunohistochemical stains of the lymph node were positive for CLA, Kp-1, S-100, while negative for CD1a, CD3, CD20, CKER, and HMB45.
  • Treatment of this patient with ABVD chemotherapy resulted in rapid clinical improvement with a marked decrease in tumor burden after two cycles of ABVD, and a complete response after six cycles of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dendritic Cells / pathology. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12153170.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


7. Khomov DA, Sinev IuV, Sotnikov VM: [Evaluation of the small bowel in patients with Hodgkin's lymphoma during and late after chemoradiation therapy]. Vestn Rentgenol Radiol; 2008;(2-3):43-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the small bowel in patients with Hodgkin's lymphoma during and late after chemoradiation therapy].
  • The paper describes the experience in using capsule endoscopy to diagnose small bowel lesions during and after chemoradiation therapy in patients with diagnosed Hodgkin's lymphoma and an attempt to compare the current views of normal tissue response to ionizing radiation, as well as drugs used for chemotherapy.
  • [MeSH-major] Capsule Endoscopy. Hodgkin Disease / therapy. Intestinal Diseases / pathology. Intestine, Small / pathology
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Humans. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21337763.001).
  • [ISSN] 0042-4676
  • [Journal-full-title] Vestnik rentgenologii i radiologii
  • [ISO-abbreviation] Vestn Rentgenol Radiol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Kella VK, Constantine R, Parikh NS, Reed M, Cosgrove JM, Abo SM, King S: Mantle cell lymphoma of the gastrointestinal tract presenting with multiple intussusceptions--case report and review of literature. World J Surg Oncol; 2009;7:60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma of the gastrointestinal tract presenting with multiple intussusceptions--case report and review of literature.
  • BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin's lymphoma that originates from small to medium sized lymphocytes located in the mantle zone of the lymph node.
  • Extra nodal involvement is present in the majority of cases, with a peculiar tendency to invade the gastro-intestinal tract in the form of multiple lymphomatous polyposis.
  • Few cases of mantle cell lymphoma presenting with intussuception have been reported.
  • Here we present a rare case of multiple intussusceptions caused by mantle cell lymphoma and review the literature of this disease.
  • The histology and immuno-histochemistry of the excised small and large bowel revealed mantle cell lymphoma with multiple lymphomatous polyposis and positivity to Cyclin D1 marker.
  • The patient was successfully treated with Rituximab-CHOP chemotherapy and remains in complete remission at one-year follow-up.
  • CONCLUSION: This is a rare case of intestinal lymphomatous polyposis due to mantle cell lymphoma presenting with multiple small bowel intussusceptions.
  • Our case highlights laparoscopic-assisted bowel resection as a potential and feasible option in the multi-disciplinary treatment of mantle cell lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / complications. Ileal Diseases / etiology. Intussusception / etiology. Lymphoma, Mantle-Cell / complications


9. Chen CQ, Yin L, Peng CH, Zhao R, Chen GM, Zhou HJ, Li HW: [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases].
  • OBJECTIVE: To study the clinical characteristics,treatment and prognosis of primary non-Hodgkin's lymphoma of small bowel.
  • METHODS: The records of 34 patients with a confirmed diagnosis of primary non-Hodgkin's lymphoma of small bowel, registered between Jan.
  • RESULTS: Twenty-seven patients had B-cell lymphoma and 7 had T-cell lymphoma of the small bowel.
  • The major symptoms included abdominal pain and intestinal obstruction.
  • According to Ann Arbor staging classification, 22 patients belonged to stage I~II, including 20 cases of B-cell lymphoma and 2 cases of T-cell lymphoma, and 12 patients belonged to stage III~IV, including 7 cases of B-cell lymphoma and 5 cases of T-cell lymphoma.
  • Compared with T-cell lymphoma patients, B-cell lymphoma patients had lower lymphoma stages (P<0.05).
  • Fourteen patients were treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy, and 8 patients were treated with Rituximab at the same time.
  • T-cell lymphoma patients were more often treated with emergent operation than B-cell lymphoma patients would (P<0.05).
  • It happened more frequently that B-cell lymphoma patients reached complete remission and their accumulative survival rate was longer than T-cell lymphoma patients did (P<0.05).
  • CONCLUSION: Patients with stages I and II B-cell lymphoma of small bowel respond well to surgery and chemotherapy, and the treatment and prognosis of patients with T-cell lymphoma of small bowel are unsatisfactory.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520384.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Greco L, Maggi P, Ialongo P, Lospalluti M, Polizzi RA, Catalano G: Acute onset of non-Hodgkin's lymphoma with bowel perforation in a patient with over 15 years' HIV positivity. A case report. Chir Ital; 2002 Nov-Dec;54(6):893-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute onset of non-Hodgkin's lymphoma with bowel perforation in a patient with over 15 years' HIV positivity. A case report.
  • The authors report a rare case of acute onset of ileal non-Hodgkin's lymphoma with acute abdomen due to bowel perforation.
  • The patient had been on continuous, differentiated pharmacological treatment for the previous 5 years, and in the last month had had repeated episodes of fever with no clear aetiopathogenesis.
  • The patient was admitted as an emergency case with a picture of acute abdomen and was immediately operated on; ileal perforation due to multiple lymphomatous lesions in the small bowel was diagnosed.
  • The histological diagnosis was large-cell non-Hodgkin's lymphoma type B.
  • After the operation, the patient was treated by chemotherapy and, currently, after a 12-month follow-up, is in good general condition.
  • [MeSH-major] HIV Seropositivity / complications. Intestinal Neoplasms / complications. Intestinal Perforation / etiology. Lymphoma, AIDS-Related / complications. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Acute Disease. Adult. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613342.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 27
  •  go-up   go-down


11. Liauw SL, Yeh AM, Morris CG, Olivier KR, Mendenhall NP: Whole-abdomen radiotherapy for non-Hodgkin's lymphoma using twice-daily fractionation. Int J Radiat Oncol Biol Phys; 2006 Dec 1;66(5):1440-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-abdomen radiotherapy for non-Hodgkin's lymphoma using twice-daily fractionation.
  • PURPOSE: To report the tolerability and efficacy of twice-daily whole-abdomen irradiation (WAI) for non-Hodgkin's lymphoma (NHL).
  • METHODS AND MATERIALS: Of 123 patients treated for NHL with WAI, 37% received previous chemotherapy, 28% received WAI as part of comprehensive lymphatic irradiation (CLI), and 32% received WAI for palliation.
  • The median dose to the whole abdomen was 25.0 Gy, followed by a median tumor boost of 9.8 Gy in 58 patients.
  • Fractionation was 1.0 Gy once daily (54%) or 0.8 Gy twice daily (46%).
  • Median time of WAI was 42 days for once-daily treatment and 32 days for twice-daily treatment.
  • Overall, acute thrombocytopenia was the most frequent side effect of treatment; 24 of 96 patients (25%) with available hematologic data had Grade 3+ toxicity.
  • There was no acute Grade 3 gastrointestinal toxicity and no late small bowel obstruction.
  • Multiple regression indicated that patients with four or less involved sites and disease size < or =6 cm had improved local control and overall survival.
  • CONCLUSIONS: Twice-daily WAI using 0.8 Gy/fraction does not appear to have any greater toxicity compared with once-daily treatment using 1 Gy/fraction.
  • Small doses per fraction (0.8-1 Gy/fx) are effective, tolerated well in the acute setting, and associated with a low rate of late toxicity.
  • [MeSH-major] Abdomen. Lymphoma, Non-Hodgkin / radiotherapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997504.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Mori M, Niitsu N, Takagi T, Tomiyama J, Matsue T, Nakagawa Y, Okamoto R: Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma; 2001 Apr;41(3-4):359-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma.
  • While CHOP therapy is effective for malignant lymphoma, the optimum schedule for elderly patients remains controversial.
  • The present study investigated the usefulness of reduced-dose CHOP therapy for elderly patients.
  • Previously untreated patients aged 65 years or older with intermediate to high-grade non-Hodgkin's lymphoma were given up to 6 courses of reduced-dose CHOP therapy at 3-week intervals.
  • Fifty-seven patients were evaluable and the scheduled therapy was completed in 37.
  • Grade 3 cardiac plus renal failure, grade 3 peritonitis due to small bowel perforation, and grade 3 liver dysfunction occurred in 1 patient each.
  • In conclusion, it seems that in the elderly patients with non-Hodgkin's lymphoma, response to reduced-dose ((5/6) dose) CHOP therapy is comparable to that for standard CHOP in younger adults, mainly because of improved dose-intensity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Age Factors. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Female. Humans. Male. Pilot Projects. Prednisone / administration & dosage. Prednisone / toxicity. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Vincristine / toxicity

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378549.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Kingsley E, Richards D, Garbo L, Gersh R, Robbins G, Leopold L, Brill J, Di Bella N: An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol; 2009 May 20;27(15_suppl):8582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL).
  • : 8582 Background: Bcl-2 family proteins are overexpressed in the majority of patients with FL and contribute to resistance to therapy.
  • METHODS: Patients with untreated FL who did not require immediate chemotherapy were eligible.
  • Treatment consisted of an induction cycle of AT-101 (30mg po daily × 21) and R (375 mg/m<sup>2</sup> weekly × 4) followed by up to 4 maintenance cycles of AT-101 (30mg po daily × 21) and R (375 mg/m<sup>2</sup>) every 8 weeks in nonprogressors.
  • Endpoints evaluated the response rate (RR) at week 8 (primary), overall response rate (ORR), molecular response rate (BCL-2JH rearrangement in blood and bone marrow), and safety of the combination.
  • RESULTS: 23 pts enrolled: median age 64 yrs; FLIPI 0-5: 0%/17%/65%/13%/4%; Grade 1/2: 61%/39%; bulky disease (>5cm<sup>3</sup>): 35%; stage: 1-4 4%/4%/30%/61%; bone marrow + 48%.
  • Grade 3/4 AEs that occurred in ≥2 pts: nausea 4(17%), vomiting 2(9%), abdominal pain 2(9%), fatigue 2(9%), and small bowel obstruction 2(9%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962265.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Cadoo KA, Lowery MA, Cumiskey J, McCaffrey J, Carney DN: Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract. J Clin Oncol; 2009 May 20;27(15_suppl):e19516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract.
  • : e19516 Background: Anthracycline based chemotherapy is the treatment of choice for aggressive primary lymphomas of the GI tract, with surgery reserved for management of complications.
  • We report long term follow up of 71 cases of primary GI NHL treated with chemotherapy and/or surgery.
  • Median age at diagnosis was 60 (15-83).
  • The 8 patients with MALT were treated with single agent chemotherapy; 7 (88%) are alive at median follow up of 8.5 years (2-16).
  • Of the aggressive lymphomas (63), all patients with T cell lymphoma had small bowel as primary site and histological evidence of celiac associated enteropathy, even in the absence of known celiac disease.
  • Primary sites of DLBCL were stomach 35 (67%), small bowel 11 (21%) & colon 6 (12%).
  • 39 (62%) patients underwent surgery at diagnosis due to acute presentation with perforation, bleeding or obstruction, or to obtain histology.
  • Following confirmed diagnosis, 61 patients received anthracycline based chemotherapy.
  • 2 patients with T cell lymphoma presented with perforation, were treated with surgery only and died of rapid disease progression.
  • Of the 63 patients with aggressive NHL, 37 (59%) remain alive & disease free at median follow up of 13 years (1-24).
  • 35 (67%) patients with DLBCL are alive & disease free.
  • Only 2 (18%) of the T cell lymphomas are alive & disease free.
  • 5 deaths in the DLBCL group were not related to cancer or treatment.
  • All deaths in the T cell group were due to progressive disease.
  • There was no difference in survival between patients treated with chemotherapy only and those who also underwent surgery.
  • CONCLUSIONS: Patients with aggressive primary B cell GI NHL have almost 70 % survival following anthracycline based chemotherapy.
  • However, in contrast, coeliac enteropathy associated T-cell lymphomas present with rapidly progressive disease & have a survival of < 20% with chemotherapy and/or surgery.
  • A novel therapeutic approach is required to improve outcome in this group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Hata S, Pietsch J, Shankar S: Intestinal complications in children undergoing chemotherapy for mediastinal non-Hodgkin's lymphoma. Pediatr Hematol Oncol; 2004 Dec;21(8):707-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal complications in children undergoing chemotherapy for mediastinal non-Hodgkin's lymphoma.
  • Toxicities involving gastrointestinal tract are common in patients undergoing aggressive chemotherapy for cancer.
  • However, it is uncommon to develop severe ulceration or perforation of the small intestine in absence of direct involvement of the bowel with the malignancy.
  • The authors describe two children who developed severe gastrointestinal complications requiring surgical intervention following initial chemotherapy for non-Hodgkin's lymphoma.
  • Both patients had no evidence of small bowel involvement by lymphoma on clinical staging.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Intestinal Diseases / chemically induced. Lymphoma, Non-Hodgkin / complications. Mediastinal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739625.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down


16. Bai M, Katsanos KH, Economou M, Kamina S, Balli C, Briasoulis E, Kappas AM, Agnantis N, Tsianos EV: Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature. Scand J Gastroenterol; 2006 Jul;41(7):866-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature.
  • We present the case of a 35-year-old man with Crohn's disease diagnosed at the age of 27, several months after an operation for small-bowel adenocarcinoma.
  • Seven years after the adenocarcinoma diagnosis, the patient presented with severe continuous anal pain and diarrhea.
  • In parallel with antibiotic administration, the patient was given treatment with Infliximab, but without clinical symptom amelioration.
  • Sigmoidoscopy and subsequent biopsies from an ulcerated rectal area supported the diagnosis of Epstein-Barr virus-positive (EBV+) primary Hodgkin's lymphoma.
  • Infliximab administration was immediately discontinued and the patient underwent oncological follow-up and began a course of chemotherapy.
  • Only a few cases with primary gastrointestinal Hodgkin's lymphoma in Crohn's disease patients have so far been reported, including a variety of scenarios on the causal relationship including disease duration, presence of EBV, long-term immunosuppressive treatment and, recently, anti-TNFalpha administration.
  • [MeSH-major] Crohn Disease / complications. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / complications. Hodgkin Disease / virology. Rectal Neoplasms / virology
  • [MeSH-minor] Adult. Humans. Immunosuppressive Agents. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / virology

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785203.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 28
  •  go-up   go-down


17. Aguayo P, Ho B, Fraser JD, Gamis A, St Peter SD, Snyder CL: Bowel obstruction after treatment of intra-abdominal tumors. Eur J Pediatr Surg; 2010 Jul;20(4):234-6
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel obstruction after treatment of intra-abdominal tumors.
  • BACKGROUND: Tumors of the solid viscera are one of the most common types of pediatric malignancies.
  • Due to the intra-abdominal location of many of these neoplasms, laparotomy and/or bowel resection are often necessary, predisposing patients to postoperative intestinal obstruction.
  • Additionally, chemotherapy and radiation therapy may lead to acute and chronic bowel injury, also potentially predisposing these patients to postoperative bowel obstruction.
  • METHODS: A retrospective data analysis of all patients diagnosed with intra-abdominal Wilms' tumor, rhabdomyosarcoma, neuroblastoma, and Hodgkin's and non-Hodgkin's lymphoma in a single institution from 1997 to 2007 was conducted.
  • Data collected included demographic factors, operations, incidence of small bowel obstruction (SBO) and the use of adjuvant or neoadjuvant chemoradiation therapy.
  • Patients who developed SBO were compared to those who did not develop obstruction.
  • Data comparisons were analyzed statistically using Fisher's exact test, 2-tailed Student's t-Test, or chi-square proportional analysis with significance reported for p<0.05.
  • Mean age at diagnosis was 8.1+/-5.8 years.
  • Tumor distribution was as follows: Wilms' tumor: 56 (19%); non-Hodgkin's lymphoma: 71 (24%); Hodgkin's lymphoma: 64 (22%); rhabdomyosarcoma: 32 (11%); and neuroblastoma: 68 (24%).
  • There were a total of 12 bowel obstructions in 11 patients (3.7%).
  • Children with bowel obstruction were more likely to be male (4.5:1, p=0.061) and younger (4.2 years versus 8.1 years; p=0.087).
  • Wilms' tumor accounted for 45% of patients with bowel obstruction, but made up only 19% of the study population.
  • The incidence of bowel obstruction in patients with Wilms' tumor was 8.9% compared to an overall incidence of 3.8% (p=0.043).
  • CONCLUSION: Bowel obstruction is relatively uncommon after intra-abdominal malignancies in children.
  • Wilms' tumor, rhabdomyosarcoma and Burkitt's lymphoma appear to be associated with the highest risk of bowel obstruction.
  • [MeSH-major] Abdominal Neoplasms / surgery. Intestinal Obstruction / etiology. Laparotomy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496318.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M, German Multicenter Study Group: Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol; 2001 Sep 15;19(18):3861-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92.
  • PURPOSE: The study was initiated to obtain epidemiologic data and information on anatomic and histologic distribution, clinical features, and treatment results in patients with primary gastrointestinal non-Hodgkin's lymphomas (PGI NHL).
  • Radiotherapy and chemotherapy were stratified according to histologic grading, stage, and whether surgery had been carried out or not.
  • Within the intestine, the small bowel and the ileocecal region were involved in 8.6% and 7.0% of the cases, respectively.
  • Forty percent of PGL were of low-grade mucosa-associated lymphatic tissue type.
  • Most intestinal NHL were germinal-center lymphomas.
  • In gastric and ileocecal lymphoma, event-free (EFS) and overall survival (OS) were significantly higher as compared with the small intestine or MGI (median time of observation, 51 months).
  • In PGL, localized disease was prognostic for EFS and OS.
  • Numbers in intestinal lymphomas were too small for subanalyses.
  • Larger studies are needed for stages III and IV and for intestinal NHL.
  • A uniform reporting system for PGI NHL, in terms of definitions and histologic and staging classifications, is needed to facilitate comparison of treatment results.
  • [MeSH-major] Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11559724.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT: CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol; 2003 Sep;82(9):585-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
  • In 60% of low-grade B lymphomas in which rituximab was effective at first, there was no clinical response in a second treatment and a few cases of follicular lymphomas (FL) with transformation to diffuse large B-cell lymphoma (DLBCL) have been reported.
  • We describe a new case and hypothesize about the mechanisms of transformation: a 52-year-old man, in follow-up during 8 years for FL, who after rituximab treatment and complete remission of FL showed progressive disease involving the liver and duodenal mucosa.
  • Immunohistochemical and molecular studies were performed on paraffin-embedded tissue samples of lymph nodes, the small intestine, and liver tumors.
  • After rituximab treatment, biopsies of a liver lesion and the small bowel both showed CD20-negative large B-cell lymphoma.
  • The rapid relapse with the same rearrangement of IgH seems to support the interpretation that the change of grade of lymphoma and loss of CD20 expression occurred before rituximab treatment.
  • The existence of a varying proportion of a CD20-negative cell population in every B-cell lymphoma which does not respond to rituximab should therefore be considered.
  • The reduction of CD20 expression could be a resistance mechanism to rituximab retreatment in DLBCL as a consequence of the progression of low-grade B-cell non-Hodgkin's lymphoma (B-NHL).
  • It is necessary to perform new biopsies to evaluate CD20 expression in relapse or the progression of B-cell lymphoma after rituximab treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / analysis. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12898184.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


20. Novakovic BJ, Novakovic S, Frkovic-Grazio S: A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep; 2006 Jul;16(1):191-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas.
  • Intestinal T cell lymphomas are rare, but highly aggressive in their clinical course.
  • Generally diagnosed in advanced stages and presenting as surgical emergencies, they also respond poorly to standard anti-lymphoma therapies.
  • Since these lymphomas are still not well characterized, we aimed our retrospective research at the evaluation of clinical features and treatment response in patients with intestinal T cell lymphomas diagnosed between February 1996 and November 2004.
  • Details of history, physical examination, staging investigation, treatment and outcome were taken from patient records.
  • Ten (67%) patients had enteropathy-associated T cell lymphoma (EATL) and 5 (33%) had peripheral T cell lymphoma (PTCL).
  • Surgery was performed on 11 patients with 8 cases on an emergency basis; all visible disease was resected in only 3 patients.
  • In the continuation of treatment, all 15 patients received chemotherapy (predominantly CHOP).
  • Six patients were treated with field radiotherapy as a part of the first treatment.
  • In total, complete response was achieved in 6 patients (40%) with a median duration of 5.3 months (range, 2 to 12 months), stable disease in 3 patients (20%), and progressive disease in 6 patients (40%).
  • Results were better in patients with limited disease.
  • The most frequent treatment complications were small bowel perforation, obstruction, gastrointestinal bleeding, and infection.
  • Even though some patients underwent second- and third-line treatment, 13 (87%) of the total 15 patients died from progressive disease or complications of treatment.
  • The prognosis and standard treatment of patients with intestinal T cell lymphomas are unsatisfactory with only a few long-term survivors.
  • Therefore, earlier diagnosis and the development of more effective treatments are urgently required to improve the prospects of these patients.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786145.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


21. Sandborn WJ, Loftus EV: Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut; 2004 Jun;53(6):780-2
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.
  • Patients with moderate to severely active Crohn's disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Crohn Disease / drug therapy. Gastrointestinal Agents / adverse effects
  • [MeSH-minor] Humans. Infliximab. Lymphoma, Non-Hodgkin / chemically induced. Opportunistic Infections / chemically induced. Risk Factors

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2003 Jul;52(7):998-1002 [12801957.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3151-8 [12483718.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1583-90 [14724808.001]
  • [Cites] N Engl J Med. 2004 Feb 26;350(9):876-85 [14985485.001]
  • [Cites] Gut. 2004 Jun;53(6):849-53 [15138212.001]
  • [Cites] N Engl J Med. 1980 May 1;302(18):981-7 [6102739.001]
  • [Cites] Gastroenterology. 1984 Feb;86(2):249-66 [6140202.001]
  • [Cites] Gastroenterology. 1985 Jun;88(6):1818-25 [3922845.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):2015-9 [2004319.001]
  • [Cites] Gastroenterology. 1992 Sep;103(3):954-60 [1499945.001]
  • [Cites] Gut. 1992 Sep;33(9):1226-8 [1427376.001]
  • [Cites] Gut. 1993 Aug;34(8):1081-5 [8174958.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1675-9 [7958678.001]
  • [Cites] Lancet. 1996 Jan 27;347(8996):215-9 [8551879.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1339-45 [8613037.001]
  • [Cites] Scand J Gastroenterol. 1996 Apr;31(4):372-5 [8726306.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1029-35 [9321530.001]
  • [Cites] Gut. 1998 Feb;42(2):175-9 [9536940.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1161-8 [9609752.001]
  • [Cites] N Engl J Med. 1999 May 6;340(18):1398-405 [10228190.001]
  • [Cites] Gastroenterology. 1999 Oct;117(4):761-9 [10500056.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):320-7 [12891531.001]
  • [Cites] Gut. 2000 Oct;47(4):514-9 [10986211.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2308-12 [11007233.001]
  • [Cites] Am J Gastroenterol. 2001 Feb;96(2):501-7 [11232697.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Am J Gastroenterol. 2001 Mar;96(3):722-9 [11280541.001]
  • [Cites] Inflamm Bowel Dis. 2001 May;7(2):83-8 [11383595.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1098-104 [11596589.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1080-7 [11677199.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):72-7 [11781282.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Jan;16(1):51-60 [11856078.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1808-14 [12055588.001]
  • [Cites] Arthritis Rheum. 2002 Oct;46(10):2565-70 [12384912.001]
  • [CommentOn] Gut. 2004 Jun;53(6):849-53 [15138212.001]
  • (PMID = 15138201.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  • [Other-IDs] NLM/ PMC1774089
  •  go-up   go-down


22. Kumar R, Xiu Y, Potenta S, Mavi A, Zhuang H, Yu JQ, Dhurairaj T, Dadparvar S, Alavi A: 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med; 2004 Nov;45(11):1796-803
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
  • (18)F-FDG PET is highly sensitive and specific for evaluation of the treatment response of nodal and extranodal diseases in patients with malignant lymphomas.
  • However, no data are available in the literature with regard to (18)F-FDG PET for evaluation of the treatment response in patients with lymphomas with gastrointestinal tract (GIT) involvement.
  • This study was undertaken to investigate the usefulness of (18)F-FDG PET in monitoring the response to the treatment of lymphomas in this setting.
  • METHODS: We retrospectively analyzed 19 patients with different types of lymphomas (10 diffuse large B-cell lymphomas, 4 follicular lymphomas, 3 mantle cell lymphomas, and 2 Hodgkin's disease) involving GIT.
  • Among 19 patients, 4 had gastric involvement, 13 had small bowel involvement, and 2 had small bowel plus colon involvement by lymphomas.
  • All patients underwent (18)F-FDG PET before and after the completion of therapy.
  • Posttreatment CT scans were negative for 10 patients but showed persistent disease in the remaining 9 patients.
  • Of the 9 patients who showed persistent disease, 6 (67%) relapsed and 3 (33%) remained in remission after the mean follow-up of 20 mo.
  • Patients with positive (18)F-FDG PET results had statistically significantly lower disease-free survival (DFS) (0%) than did those with positive CT results (33%) (P = 0.04).
  • CONCLUSION: A positive (18)F-FDG PET scan after the completion of chemotherapy in patients with lymphomas with GIT involvement is a strong predictor of relapse. (18)F-FDG PET has higher diagnostic accuracy than CT in the detection of residual disease after therapy.
  • Despite the mild physiologic (18)F-FDG uptake in the GIT, (18)F-FDG PET has potential value in monitoring the response to treatment in patients with GIT lymphomas, particularly when pretreatment PET results are positive.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fluorodeoxyglucose F18. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / radionuclide imaging. Lymphoma / drug therapy. Lymphoma / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534046.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Palanivelu C, Rangarajan M, Senthilkumar R, Annapoorni S: Laparoscopic management of an obstructing granulocytic sarcoma of the jejunum causing intussusception in a nonleukemic patient: report of a case. Surg Today; 2009;39(7):606-9
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulocytic sarcoma of the gastrointestinal tract frequently involves the small intestine and often presents with abdominal pain and obstruction.
  • This type of manifestation has never before been reported.
  • The initial pathological findings were high-grade non-Hodgkin's lymphoma; immunohistochemistry confirmed a diagnosis of granulocytic sarcoma.
  • This condition is often mistaken for lymphoma and confirmation is necessary by immunohistochemistry.
  • Chemotherapy is the treatment of choice and surgery is indicated only in the event of complications, such as bowel obstruction, bleeding, or perforation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):865-6 [10690184.001]
  • [Cites] J Am Acad Dermatol. 1997 Aug;37(2 Pt 2):308-11 [9270534.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] J Nippon Med Sch. 2000 Oct;67(5):392-5 [11031375.001]
  • [Cites] Med Clin (Barc). 1995 Mar 18;104(10):377-80 [7707732.001]
  • [Cites] Am J Gastroenterol. 1998 Dec;93(12 ):2586-8 [9860434.001]
  • [Cites] Chirurg. 2002 Nov;73(11):1127-31 [12430065.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):555-9 [1985052.001]
  • [Cites] Hong Kong Med J. 2005 Jun;11(3):204-6 [15951586.001]
  • [Cites] J Fla Med Assoc. 1997 Feb;84(2):111-4 [9066237.001]
  • [Cites] World J Surg. 2000 Apr;24(4):421-9 [10706914.001]
  • [Cites] Am Surg. 2001 Aug;67(8):764-6 [11510579.001]
  • [Cites] Gastroenterol Hepatol. 2003 Jun-Jul;26(6):347-50 [12809571.001]
  • (PMID = 19562450.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Psyrri A, Papageorgiou S, Economopoulos T: Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol; 2008 Dec;19(12):1992-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management.
  • Gastrointestinal lymphoma is the most common form of extranodal lymphoma, accounting for 30%-40% of cases.
  • The most commonly involved site is the stomach (60%-75% of cases), followed by the small bowel, ileum, cecum, colon and rectum.
  • The most common histological subtypes are diffuse large B-cell lymphoma (DLBCL) and marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT).
  • Helicobacter pylori infection has been implicated in the pathogenesis of MALT gastric lymphoma, but its role in gastric diffuse large B-cell non-Hodgkin's lymphoma (NHL) is controversial.
  • The therapeutic approach for patients with gastric NHL has been revised over the last 10 years.
  • Conservative treatment with anthracycline-based chemotherapy alone or in combination with involved-field radiotherapy has replaced gastrectomy as standard therapy in cases with DLBCL.
  • Nevertheless, various therapeutic aspects for primary gastric lymphomas are still controversial and several questions remain unanswered.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5061-6 [16051953.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6370-8 [16155022.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6415-20 [16155028.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1345-53 [16174856.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8018-24 [16204012.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8442-6 [16293875.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):721-6 [16556173.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2096-101 [17071482.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2110-4 [17071484.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2140-6 [17071488.001]
  • [Cites] Oncology. 2006;70(6):411-7 [17220639.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):65-71 [17339119.001]
  • [Cites] Gut. 2007 Dec;56(12):1685-7 [17639089.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):895-901 [10705011.001]
  • [Cites] Hematol Oncol. 2000 Mar;18(1):15-9 [10797526.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] J Clin Gastroenterol. 1994 Mar;18(2):99-104 [8189031.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Hematol Oncol. 1995 May-Jun;13(3):153-63 [7622145.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):3-11 [8988720.001]
  • [Cites] Histopathology. 1997 May;30(5):425-9 [9181363.001]
  • [Cites] Ann Oncol. 1997 May;8(5):419-21 [9233518.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):979-85 [9402171.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1916-21 [9586910.001]
  • [Cites] Leuk Lymphoma. 1999 May;33(5-6):531-41 [10342580.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5785-94 [10523859.001]
  • [Cites] J Pathol. 2005 Jan;205(2):255-74 [15643667.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1979-83 [15668468.001]
  • [Cites] Acta Haematol. 2005;113(2):97-103 [15802887.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Recent Results Cancer Res. 2000;156:99-103 [10802868.001]
  • [Cites] J Clin Pathol. 2000 Mar;53(3):187-90 [10823136.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):95-102 [11145257.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):39-40 [11197361.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1600-9 [11250988.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2041-8 [11283137.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1182-7 [11493468.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4245-51 [11709568.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B100-5 [11757688.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1094-8 [12176789.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1120-7 [12176793.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3872-7 [12228207.001]
  • [Cites] Blood. 2003 May 15;101(10):3875-6 [12531812.001]
  • [Cites] Gut. 2003 Jun;52(6):912-3 [12740354.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):11-6 [14695844.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1086-90 [15205203.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Oncology. 2004;66(6):476-80 [15452377.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Br J Cancer. 1985 Sep;52(3):391-7 [3840030.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Am J Pathol. 1990 May;136(5):1153-64 [2349966.001]
  • [Cites] Eur J Cancer. 1990;26(7):855 [2145918.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1159-70 [1936785.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Histopathology. 1992 Jan;20(1):29-34 [1737623.001]
  • [Cites] Lancet. 1992 Apr 4;339(8797):834-5 [1347858.001]
  • [Cites] Histopathology. 1992 Nov;21(5):415-21 [1452124.001]
  • [Cites] Oncology. 1992;49(6):484-8 [1465289.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • (PMID = 18647965.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC2733120
  •  go-up   go-down






Advertisement